Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 22 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that the USFDA has granted Orphan Drug Designation to Usnoflast for treating amyotrophic lateral sclerosis (ALS). This designation provides eligibility for development incentives, including tax credits and potential marketing exclusivity upon FDA approval. The company emphasizes its commitment to developing Usnoflast to address the urgent needs of ALS patients, who face severe health challenges.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 22, 2025, titled "Zydus announces USFDA Orphan Drug Designation to Usnoflast for the treatment of Amyotrophic Lateral Sclerosis (ALS)".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases